Stay updated on Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page.

Latest updates to the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page
- CheckyesterdayChange DetectedMinor revision history updated: added v3.3.4 and removed v3.3.3; no substantive changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded new trial locations: New Hampshire, Wisconsin, and Badalona, and updated the location sections accordingly. The HHS Vulnerability Disclosure link was removed, and the page revision was updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check44 days agoChange DetectedRevision: v3.3.2 is now displayed on the page, replacing v3.3.1. This is a minor site update and does not alter study information.SummaryDifference0.0%

- Check52 days agoChange DetectedThe Publications section now notes that items are auto-filled from PubMed and may not all be about the study, and the revision version is updated to v3.3.1.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the government funding status notice banner from the page; this banner did not affect the trial details, eligibility criteria, or study results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check73 days agoChange DetectedNo significant changes detected between the old and new screenshots of the Study Details page; the main sections appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bemcentinib-Pembrolizumab Combo in Advanced NSCLC Clinical Trial page.